Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy.

PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without dexrazoxane in treating children who have Hodgkin's disease.


Options:
A: Arm Label: Cancer survivors; Type: N/A; Interventions: N/A | Arm Label: Sibling Controls; Type: N/A; Interventions: N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisone, Drug: vincristine sulfate, Radiation: radiation therapy | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Drug: cyclophosphamide, Drug: dexrazoxane hydrochloride, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisone, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: dexrazoxane hydrochloride; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1, Arm 2
C: Intervention Type: DRUG; Name: asparaginase (E. Coli); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: asparaginase (Erwina); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dexrazoxane; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: cranial radiation (once daily fractionation); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: cranial radiation (twice-daily fractionation); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Intrathecal chemotherapy without radiation; Assigned to Arm(s): N/A
D: Arm Label: Ancillary-Correlative (laboratory biomarker analysis); Type: N/A; Interventions: Other: Assessment of Therapy Complications, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Other: Questionnaire Administration | Intervention Type: OTHER; Name: Assessment of Therapy Complications; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis)

Answer: B